Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 13/20 | 1.00 |
| ▸ | NPC1 | O15118 | 2/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.71 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.71 |
| ▸ | RAB9A | P51151 | 2/20 | 0.71 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.71 |
| ▸ | FSCN1 | Q16658 | 1/20 | 0.71 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.71 |
| ▸ | HSD17B1 | P14061 | 3/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.68 |
| ▸ | HTT | P42858 | 1/20 | 0.68 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.66 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.66 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.66 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.66 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.65 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.64 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.64 |
| ▸ | SULT1A1 | P50225 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3804150 | 0.88 | PIK3CG (0.80) | DYRK1ANPC1CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL16992945 | 0.88 | DYRK1A (1.00) | DYRK1ANPC1CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL31060991 | 0.88 | DYRK1A (1.00) | DYRK1ANPC1CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL544349 | 0.86 | DYRK1A (0.75) | DYRK1ACYP3A4CYP2C19CYP2C9HSD17B1 | |
| SCHEMBL3716998 | 0.85 | PIK3CG (0.79) | DYRK1ANPC1CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL20887499 | 0.85 | DYRK1A (0.72) | DYRK1ANPC1CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL2175580 | 0.84 | DYRK1A (1.00) | DYRK1ANPC1CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL27717411 | 0.84 | DYRK1A (0.73) | DYRK1ACYP3A4CYP2C19CYP2C9HSD17B1 | |
| SCHEMBL14539566 | 0.84 | DYRK1A (0.72) | DYRK1ACYP3A4CYP2C19CYP2C9HSD17B1 | |
| SCHEMBL4501407 | 0.83 | DYRK1A (0.71) | DYRK1ANPC1CYP1A2CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140348748-A1 | BETA-AMYLOID IMAGING AGENTS, METHODS OF MANUFACTURE, AND METHODS OF USE THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2014-11-27 | — | — | US | disclosed |
| US-20140348748-A1 | BETA-AMYLOID IMAGING AGENTS, METHODS OF MANUFACTURE, AND METHODS OF USE THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2014-11-27 | — | — | US | disclosed |
| WO-2013040183-A1 | BETA-AMYLOID IMAGING AGENTS, METHODS OF MANUFACTURE, AND METHODS OF USE THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2013-03-21 | — | — | WO | disclosed |
| US-8110571-B2 | Tyrosine kinase inhibitors; antiproliferation agents; metabolism diseases; antiallergens; central nervous system disorders; vision and skin disorders; antiarthritic agents | AVENTIS PHARMA S.A. (FR) | 2012-02-07 | — | — | US | disclosed |
| US-20080194555-A1 | Novel Benzimidazole and Benzothiazole Derivatives, Method for Preparing Same, Use Thereof as Drugs, Pharmaceutical Compositions and Novel Use Especially as c-MET Inhibitors | AVENTIS PHARMA S.A. (FR) | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194555-A1 | Novel Benzimidazole and Benzothiazole Derivatives, Method for Preparing Same, Use Thereof as Drugs, Pharmaceutical Compositions and Novel Use Especially as c-MET Inhibitors | MET, KIT, MERTK | DYRK1A 3467/4885NPC1 508/4885CYP1A2 261/4885 |
| US-20140348748-A1 | BETA-AMYLOID IMAGING AGENTS, METHODS OF MANUFACTURE, AND METHODS OF USE THEREOF | APP, APBA1, IAPP | DYRK1A 4629/4885NPC1 332/4885CYP1A2 2863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.